Clinical trials
Phase 3 Carcinoma, Non-Small-Cell Lung trials in Denmark
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
42 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 2 |
| 2006 | 4 |
| 2007 | 2 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 22 |
| Recruiting | 9 |
| Active, not recruiting | 6 |
| Terminated | 4 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 7 |
| AbbVie | 3 |
| AstraZeneca | 3 |
| Boehringer Ingelheim | 3 |
| Eli Lilly and Company | 3 |
| Novartis Pharmaceuticals | 3 |
| Pfizer | 3 |
| EMD Serono Research & Development Institute, Inc. | 2 |
| Genzyme, a Sanofi Company | 2 |
| Merck Sharp & Dohme LLC | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 42 |
| Lung Neoplasms | 8 |
| Neoplasm Metastasis | 5 |
| Neoplasms | 3 |
| Carcinoma | 2 |
| Lung Diseases | 2 |
| Adenocarcinoma | 1 |
| Adenocarcinoma of Lung | 1 |
| Bronchial Neoplasms | 1 |
| Carcinoma, Bronchogenic | 1 |
Trials
Showing 1 to 25 of 42. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.